Last update April 11, 2026

N-[(1S)-1-{3-[4-Chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2- [(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Lenacapavir is an HIV-1 capsid inhibitor with antiviral activity against HIV-1. It is used with other antiretrovirals for the treatment of multidrug-resistant HIV-1 infection. It has been approved in 2022 by the EMA and FDA. Oral and subcutaneous administration: following an initial course combining both routes of administration, maintenance treatment consists of a subcutaneous dose every 6 months.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight, very high percentage of binding to plasma proteins and very large volume of distribution) make it unlikely to pass into breast milk in clinically significant quantities.de 

Plasma levels in infants of mothers treated with lenacapavir are 5% of maternal plasma levels. (Bekker 2025)

Its low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.

"Individuals with HIV who are on ART with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision". (Panel 2024 E-11).

 


See below the information of this related product:

Alternatives

We do not have alternatives for N-[(1S)-1-{3-[4-Chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2- [(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

N-[(1S)-1-{3-[4-Chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2- [(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide is Lenacapavir, Lenacapavir Sodium (LEN) in Chemical name.

Is written in other languages:

Group

N-[(1S)-1-{3-[4-Chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2- [(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide belongs to this group or family:

Tradenames

Main tradenames from several countries containing N-[(1S)-1-{3-[4-Chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2- [(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 6 - 10 %
Molecular weight 968 daltons
Protein Binding 99.8 %
VD 13.9 l/Kg
pKa 6.69 -
Tmax 4 hours
T½ 240 - 288 hours
M/P ratio 0.63 -

References

  1. Bekker LG, Moodley D, Harkoo I, Kigozi G, Louw CE, Malahleha M, Palanee-Phillips T, Panchia R, Singh N, Diallo DD, Mworeko L, Puryear S, Wong P, Arora P, Imperial M, Deaton C, Kintu A, Das M, Matovu Kiweewa F Inclusion of pregnant and lactating people in the PURPOSE 1 study: Efficacy, safety, and pharmacokinetics. J Int AIDS Soc. 2025 Jul;28 Suppl 4(Suppl 4): Abstract Supplement Abstracts from IAS 2025, the 13th IAS Conference on HIV Science, 13 - 17 July, Kigali, Rwanda & Virtual Abstract Full text (link to original source) Full text (in our servers)
  2. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2024 Abstract Full text (link to original source)
  3. Gilead. Lenacapavir. Drug Summary. 2022 Full text (in our servers)

Total visits

688

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child´s Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM